Animal models of colorectal cancer with liver metastasis

Cancer Letters

Volumn 387, Issue , 2017, Pages 114-120

  Oh, Bo Young ^a   Hong, Hye Kyung ^b   Lee, Woo Yong ^a,c   Cho, Yong Beom ^a,c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

Colorectal cancer; Genetically engineered mouse model; Liver metastasis; Mouse model; Orthotopic model; Xenografts

Indexed keywords

CANCER MODEL; COLORECTAL CANCER; GENE MUTATION; GENETICALLY ENGINEERED MOUSE STRAIN; HISTOPATHOLOGY; LIVER METASTASIS; METASTASIS POTENTIAL; MOLECULAR IMAGING; NOD SCID GAMMA MOUSE; NOD SCID MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAG1-/- MOUSE; SCID BEIGE MOUSE; SCID MOUSE; SHORT SURVEY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; X-RAY COMPUTED TOMOGRAPHY; ANIMAL; COLORECTAL TUMOR; DISEASE MODEL; HUMAN; LIVER TUMOR; PATHOLOGY; SECONDARY;

ANIMALS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; LIVER NEOPLASMS;

EID: 84957922197     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.01.048     Document Type: Review

References (86)

1. [1] Huang, M.Y., et al. DPYD, TYMS, TYMP, TK1, and TK2 genetic expressions as response markers in locally advanced rectal cancer patients treated with fluoropyrimidine-based chemoradiotherapy. Biomed Res. Int, 2013, 2013, 931028.
2. [2] Zhang, Z.J., et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 34:10 (2011), 2323–2328.
3. [3] Sui, X., et al. Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation. PLoS ONE, 9(5), 2014, e97781.
4. [4] Jemal, A., et al. Global cancer statistics. CA Cancer J. Clin 61:2 (2011), 69–90.
5. [5] Oh, B.Y., et al. Role of beta1-integrin in colorectal cancer: case-control study. Ann. Coloproctol 30:2 (2014), 61–70.
6. [6] Siegel, R., et al. Cancer statistics, 2014. CA Cancer J. Clin 64:1 (2014), 9–29.
7. [7] Kamiyama, H., et al. Molecular biomarkers for the detection of metastatic colorectal cancer cells. World J. Gastroenterol 20:27 (2014), 8928–8938.
8. [8] Li, W., et al. miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR. Oncotarget 6:27 (2015), 24448–24462.
9. [9] Lintoiu-Ursut, B., Tulin, A., Constantinoiu, S., Recurrence after hepatic resection in colorectal cancer liver metastasis – review article. J. Med. Life 8 Spec Issue (2015), 12–14.
10. [10] Chen, H., et al. Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis. Surgery 158:6 (2015), 1704–1713.
11. [11] Wanebo, H.J., et al. Meeting the biologic challenge of colorectal metastases. Clin. Exp. Metastasis 29:7 (2012), 821–839.
12. [12] Ishizu, K., et al. Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. Biol. Pharm. Bull 30:9 (2007), 1779–1783.
13. [13] van Marion, D.M., et al. Studying cancer metastasis: existing models, challenges and future perspectives. Crit. Rev. Oncol. Hematol 97 (2016), 107–117.
14. [14] Saxena, M., Christofori, G., Rebuilding cancer metastasis in the mouse. Mol Oncol 7:2 (2013), 283–296.
15. [15] Smakman, N., et al. Validation of bioluminescence imaging of colorectal liver metastases in the mouse. J. Surg. Res 122:2 (2004), 225–230.
16. [16] Richmond, A., Su, Y., Mouse xenograft models vs GEM models for human cancer therapeutics. Dis. Model. Mech 1:2–3 (2008), 78–82.
17. [17] Taketo, M.M., Edelmann, W., Mouse models of colon cancer. Gastroenterology 136:3 (2009), 780–798.
18. [18] Lee, W.Y., et al. Comparison of colorectal cancer in differentially established liver metastasis models. Anticancer Res 34:7 (2014), 3321–3328.
19. [19] Heijstek, M.W., Kranenburg, O., Borel Rinkes, I.H., Mouse models of colorectal cancer and liver metastases. Dig. Surg 22:1–2 (2005), 16–25.
20. [20] Hann, B., Balmain, A., Building ‘validated’ mouse models of human cancer. Curr. Opin. Cell Biol 13:6 (2001), 778–784.
21. [21] Rosenberg, M.P., Bortner, D., Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer). Cancer Metastasis Rev 17:3 (1998), 295–299.
22. [22] He, L., et al. Mouse models of liver cancer: progress and recommendations. Oncotarget 6:27 (2015), 23306–23322.
23. [23] Frese, K.K., Tuveson, D.A., Maximizing mouse cancer models. Nat. Rev. Cancer 7:9 (2007), 645–658.
24. [24] Maddison, K., Clarke, A.R., New approaches for modelling cancer mechanisms in the mouse. J. Pathol 205:2 (2005), 181–193.
25. [25] Cekanova, M., Rathore, K., Animal models and therapeutic molecular targets of cancer: utility and limitations. Drug Des. Devel. Ther 8 (2014), 1911–1921.
26. [26] Morton, C.L., Houghton, P.J., Establishment of human tumor xenografts in immunodeficient mice. Nat. Protoc 2:2 (2007), 247–250.
27. [27] Khanna, C., Hunter, K., Modeling metastasis in vivo. Carcinogenesis 26:3 (2005), 513–523.
28. [28] Francia, G., et al. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat. Rev. Cancer 11:2 (2011), 135–141.
29. [29] Fantozzi, A., Christofori, G., Mouse models of breast cancer metastasis. Breast Cancer Res, 8(4), 2006, 212.
30. [30] Jonkers, J., Derksen, P.W., Modeling metastatic breast cancer in mice. J. Mammary Gland Biol. Neoplasia 12:2–3 (2007), 191–203.
31. [31] Cabioglu, N., et al. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 65:15 (2005), 6493–6497.
32. [32] Orimo, A., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:3 (2005), 335–348.
33. [33] Oh, B.Y., et al. Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients. Oncotarget 6:18 (2015), 16059–16068.
34. [34] Flatmark, K., et al. Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice. Eur. J. Cancer 40:10 (2004), 1593–1598.
35. [35] Guilbaud, N., et al. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors. Clin. Cancer Res 7:8 (2001), 2573–2580.
36. [36] Park, J.Y., et al. Fluorescent-antibody targeting of insulin-like growth factor-1 receptor visualizes metastatic human colon cancer in orthotopic mouse models. PLoS ONE, 11(1), 2016, e0146504.
37. [37] Chen, H.N., et al. PDLIM1 stabilizes the E-cadherin/beta-catenin complex to prevent epithelial-mesenchymal transition and metastatic potential of colorectal cancer cells. Cancer Res, 2015.
38. [38] Fu, X., et al. Extensive liver metastasis from human colon cancer in nude and SCID mice after orthotopic onplantation of histologically-intact human colon carcinoma tissue. Anticancer Res 12:5 (1992), 1395–1397.
39. [39] Pocard, M., et al. Efficiency of orthotopic xenograft models for human colon cancers. In Vivo 10:5 (1996), 463–469.
40. [40] Kubota, T., Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation. J. Cell. Biochem 56:1 (1994), 4–8.
41. [41] Bibby, M.C., Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur. J. Cancer 40:6 (2004), 852–857.
42. [42] Khanna, C., et al. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin. Exp. Metastasis 18:3 (2000), 261–271.
43. [43] Cespedes, M.V., et al. Mouse models in oncogenesis and cancer therapy. Clin. Transl. Oncol 8:5 (2006), 318–329.
44. [44] Rashidi, B., et al. A nude mouse model of massive liver and lymph node metastasis of human colon cancer. Anticancer Res 20:2A (2000), 715–722.
45. [45] Sun, F.X., et al. An ultra-metastatic model of human colon cancer in nude mice. Clin. Exp. Metastasis 17:1 (1999), 41–48.
46. [46] Munoz, R., et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66:7 (2006), 3386–3391.
47. [47] Cruz-Munoz, W., et al. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res 68:12 (2008), 4500–4505.
48. [48] Francia, G., et al. Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines. Mol. Cancer Ther 7:10 (2008), 3452–3459.
49. [49] Fidler, I.J., Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50:19 (1990), 6130–6138.
50. [50] Chambers, A.F., et al. Critical steps in hematogenous metastasis: an overview. Surg. Oncol. Clin. N. Am 10:2 (2001), 243–255 vii.
51. [51] Kang, Y., Analysis of cancer stem cell metastasis in xenograft animal models. Methods Mol. Biol 568 (2009), 7–19.
52. [52] Cho, Y.B., et al. Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors. J. Surg. Res 187:2 (2014), 502–509.
53. [53] Marangoni, E., et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin. Cancer Res 13:13 (2007), 3989–3998.
54. [54] John, T., et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin. Cancer Res 17:1 (2011), 134–141.
55. [55] Puig, I., et al. A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. Clin. Cancer Res 19:24 (2013), 6787–6801.
56. [56] Hiroshima, Y., et al. Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. PLoS ONE, 10(2), 2015, e0117417.
57. [57] Rashidi, B., et al. An orthotopic mouse model of remetastasis of human colon cancer liver metastasis. Clin. Cancer Res 6:6 (2000), 2556–2561.
58. [58] Morikawa, K., et al. In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 48:7 (1988), 1943–1948.
59. [59] Julien, S., et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res 18:19 (2012), 5314–5328.
60. [60] Siolas, D., Hannon, G.J., Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 73:17 (2013), 5315–5319.
61. [61] Carretero, J., et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17:6 (2010), 547–559.
62. [62] Martin, E.S., et al. Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin. Cancer Res 19:11 (2013), 2929–2940.
63. [63] Van Dyke, T., Jacks, T., Cancer modeling in the modern era: progress and challenges. Cell 108:2 (2002), 135–144.
64. [64] Hung, K.E., et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc. Natl. Acad. Sci. U.S.A. 107:4 (2010), 1565–1570.
65. [65] Rampetsreiter, P., Casanova, E., Eferl, R., Genetically modified mouse models of cancer invasion and metastasis. Drug Discov. Today Dis. Model 8:2–3 (2011), 67–74.
66. [66] Markowitz, S.D., Bertagnolli, M.M., Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med 361:25 (2009), 2449–2460.
67. [67] Jonkers, J., Berns, A., Conditional mouse models of sporadic cancer. Nat. Rev. Cancer 2:4 (2002), 251–265.
68. [68] Dranoff, G., Experimental mouse tumour models: what can be learnt about human cancer immunology?. Nat. Rev. Immunol 12:1 (2012), 61–66.
69. [69] Firestone, B., The challenge of selecting the ‘right’ in vivo oncology pharmacology model. Curr. Opin. Pharmacol 10:4 (2010), 391–396.
70. [70] Talmadge, J.E., et al. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am. J. Pathol 170:3 (2007), 793–804.
71. [71] Palmiter, R.D., Brinster, R.L., Germ-line transformation of mice. Annu. Rev. Genet 20 (1986), 465–499.
72. [72] Brodie, S.G., et al. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 20:51 (2001), 7514–7523.
73. [73] Stambolic, V., et al. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten ± mice. Cancer Res 60:13 (2000), 3605–3611.
74. [74] te Velde, E.A., et al. Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br. J. Surg 89:10 (2002), 1302–1309.
75. [75] van Hensbergen, Y., et al. Rapid stereology based quantitative immunohistochemistry of dendritic cells in lymph nodes: a methodological study. Anal. Cell. Pathol 22:3 (2001), 143–149.
76. [76] Resor, L., Bowen, T.J., Wynshaw-Boris, A., Unraveling human cancer in the mouse: recent refinements to modeling and analysis. Hum. Mol. Genet 10:7 (2001), 669–675.
77. [77] Dubey, P., et al. Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc. Natl. Acad. Sci. U.S.A. 100:3 (2003), 1232–1237.
78. [78] Lewis, J.S., et al. Small animal imaging. Current technology and perspectives for oncological imaging. Eur. J. Cancer 38:16 (2002), 2173–2188.
79. [79] Weissleder, R., Scaling down imaging: molecular mapping of cancer in mice. Nat. Rev. Cancer 2:1 (2002), 11–18.
80. [80] Nyati, M.K., et al. The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther 9:13 (2002), 844–849.
81. [81] Chishima, T., et al. Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res 57:10 (1997), 2042–2047.
82. [82] Hoffman, R.M., Orthotopic transplant mouse models with green fluorescent protein-expressing cancer cells to visualize metastasis and angiogenesis. Cancer Metastasis Rev 17:3 (1998), 271–277.
83. [83] Yang, M., et al. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc. Natl. Acad. Sci. U.S.A. 97:3 (2000), 1206–1211.
84. [84] Xue, W., et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514:7522 (2014), 380–384.
85. [85] Sanchez-Rivera, F.J., Jacks, T., Applications of the CRISPR-Cas9 system in cancer biology. Nat. Rev. Cancer 15:7 (2015), 387–395.
86. [86] Mou, H., et al. Precision cancer mouse models through genome editing with CRISPR-Cas9. Genome Med, 7(1), 2015, 53.